View in EDS

Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up.

Saved in:
Bibliographic Details
Title: Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up.
Authors: Papp KA; Alliance Clinical Research and Probity Medical Research, Waterloo. Electronic address: kapapp@probitymedical.com., Blauvelt A; Oregon Medical Research Center, Portland., Puig L; Department of Dermatology, IIB Sant Pau, Hospital de la Santa Creu i Sant Pau, Barcelona., Ohtsuki M; Department of Dermatology, Jichi Medical University, Tochigi., Beissert S; Department of Dermatology, University Hospital Carl Gustav Carus, TU Dresden, Dresden., Gooderham M; SKiN Centre for Dermatology, Probity Medical Research, and Department of Medicine, Queen's University, Ontario., Amin AZ; Northwestern Medicine Dermatology, Chicago., Liu J; AbbVie Inc., North Chicago., Wu T; AbbVie Inc., North Chicago., Azam T; AbbVie Inc., North Chicago., Stakias V; AbbVie Inc., North Chicago., Espaillat R; AbbVie Inc., North Chicago., Sinvhal R; AbbVie Inc., North Chicago., Soliman AM; AbbVie Inc., North Chicago., Pang Y; AbbVie Inc., North Chicago., Chen MM; AbbVie Inc., North Chicago., Lebwohl MG; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York.
Source: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2023 Dec; Vol. 89 (6), pp. 1149-1158. Date of Electronic Publication: 2023 Aug 06.
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Mosby Country of Publication: United States NLM ID: 7907132 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-6787 (Electronic) Linking ISSN: 01909622 NLM ISO Abbreviation: J Am Acad Dermatol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37553030
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Papp+KA%22">Papp KA</searchLink>; Alliance Clinical Research and Probity Medical Research, Waterloo. Electronic address: kapapp@probitymedical.com.<br /><searchLink fieldCode="AU" term="%22Blauvelt+A%22">Blauvelt A</searchLink>; Oregon Medical Research Center, Portland.<br /><searchLink fieldCode="AU" term="%22Puig+L%22">Puig L</searchLink>; Department of Dermatology, IIB Sant Pau, Hospital de la Santa Creu i Sant Pau, Barcelona.<br /><searchLink fieldCode="AU" term="%22Ohtsuki+M%22">Ohtsuki M</searchLink>; Department of Dermatology, Jichi Medical University, Tochigi.<br /><searchLink fieldCode="AU" term="%22Beissert+S%22">Beissert S</searchLink>; Department of Dermatology, University Hospital Carl Gustav Carus, TU Dresden, Dresden.<br /><searchLink fieldCode="AU" term="%22Gooderham+M%22">Gooderham M</searchLink>; SKiN Centre for Dermatology, Probity Medical Research, and Department of Medicine, Queen's University, Ontario.<br /><searchLink fieldCode="AU" term="%22Amin+AZ%22">Amin AZ</searchLink>; Northwestern Medicine Dermatology, Chicago.<br /><searchLink fieldCode="AU" term="%22Liu+J%22">Liu J</searchLink>; AbbVie Inc., North Chicago.<br /><searchLink fieldCode="AU" term="%22Wu+T%22">Wu T</searchLink>; AbbVie Inc., North Chicago.<br /><searchLink fieldCode="AU" term="%22Azam+T%22">Azam T</searchLink>; AbbVie Inc., North Chicago.<br /><searchLink fieldCode="AU" term="%22Stakias+V%22">Stakias V</searchLink>; AbbVie Inc., North Chicago.<br /><searchLink fieldCode="AU" term="%22Espaillat+R%22">Espaillat R</searchLink>; AbbVie Inc., North Chicago.<br /><searchLink fieldCode="AU" term="%22Sinvhal+R%22">Sinvhal R</searchLink>; AbbVie Inc., North Chicago.<br /><searchLink fieldCode="AU" term="%22Soliman+AM%22">Soliman AM</searchLink>; AbbVie Inc., North Chicago.<br /><searchLink fieldCode="AU" term="%22Pang+Y%22">Pang Y</searchLink>; AbbVie Inc., North Chicago.<br /><searchLink fieldCode="AU" term="%22Chen+MM%22">Chen MM</searchLink>; AbbVie Inc., North Chicago.<br /><searchLink fieldCode="AU" term="%22Lebwohl+MG%22">Lebwohl MG</searchLink>; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%227907132%22">Journal of the American Academy of Dermatology</searchLink> [J Am Acad Dermatol] 2023 Dec; Vol. 89 (6), pp. 1149-1158. <i>Date of Electronic Publication: </i>2023 Aug 06.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Mosby%22">Mosby </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>7907132 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1097-6787 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201909622%22">01909622 </searchLink><i>NLM ISO Abbreviation: </i>J Am Acad Dermatol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37553030
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.jaad.2023.07.1024
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1149
    Titles:
      – TitleFull: Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Papp KA
      – PersonEntity:
          Name:
            NameFull: Blauvelt A
      – PersonEntity:
          Name:
            NameFull: Puig L
      – PersonEntity:
          Name:
            NameFull: Ohtsuki M
      – PersonEntity:
          Name:
            NameFull: Beissert S
      – PersonEntity:
          Name:
            NameFull: Gooderham M
      – PersonEntity:
          Name:
            NameFull: Amin AZ
      – PersonEntity:
          Name:
            NameFull: Liu J
      – PersonEntity:
          Name:
            NameFull: Wu T
      – PersonEntity:
          Name:
            NameFull: Azam T
      – PersonEntity:
          Name:
            NameFull: Stakias V
      – PersonEntity:
          Name:
            NameFull: Espaillat R
      – PersonEntity:
          Name:
            NameFull: Sinvhal R
      – PersonEntity:
          Name:
            NameFull: Soliman AM
      – PersonEntity:
          Name:
            NameFull: Pang Y
      – PersonEntity:
          Name:
            NameFull: Chen MM
      – PersonEntity:
          Name:
            NameFull: Lebwohl MG
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2023 Dec
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 1097-6787
          Numbering:
            – Type: volume
              Value: 89
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Journal of the American Academy of Dermatology
              Type: main
ResultId 1